Skip to main content

Market Access Monitor

Service of monitoring key reimbursement and HTA developments for medical devices, in-vitro diagnostic tests, and digital technologies in Europe and globally

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC released an analytical White Paper with a summary of clinical evidence requirements for Interventional Procedures Program at NICE

07 Dec 2023

Health technology assessment plays an important role in market access for medical technologies in England. National Institute for Health and Care Excellence (NICE) is the key HTA organization with several programs dedicated to the assessment of medical technologies. One of the key med tech-related programs at NICE is the Interventional Procedures Program. 

The evidence requirements in the program are not entirely clear and depend on many factors (population, level of unmet need, level of invasiveness, safety profile, and many others).

MTRC developed an analytical White Paper with a summary of clinical evidence requirements for Interventional Procedures Program at NICE. 

In this White Paper, we performed a review of five recent assessments by NICE to present the evidence requirements for medical technologies in this particular HTA program. A review of five cases is followed by recommendations in relation to evidence generation for medical technologies, market access in England, and factors influencing the decision-making of NICE. The analysis was performed in June 2023. Request an analytical White Paper and advance your understanding of European market access for medical devices.